Furthermore, our results indicate that PF-309 inhibits key signaling pathways involved in CRC progression, including the mTOR, p70 S6K, EIF4G1, NF-κB, IKB-α, c-Myc, WNT3A, and β-catenin pathways, underscoring its broad spectrum of anti-tumor effects. The gene discussed is MTOR; the disease is neoplasm.